Posted by Bob on June 22, 2010, at 2:30:30
In reply to TC-5214...future hope for depression??, posted by rovers95 on June 20, 2010, at 17:01:35
> Below is a link regarding AstraZeneca's TC-5214, which is being proposed for release in 2013 (all being well) as an augmentor for antidepressants when patients fail the initial trial, it has shown promising results in this respect so far and as someone who subscribes to the cholinergic theory of depression i believe/hope it may benefit myself and many others.
>
> http://www.news-medical.net/news/20100420/AstraZenecaTargacepts-TC-5214-for-treatment-resistant-depression-to-earn-Decision-Resources-gold-standard-status.aspx
>
> there's plenty of stuff out there on this drug, such as.
>
> http://www.medicalnewstoday.com/articles/157831.php
>
> Unlike scopolamine, which i responded to briefly but then went into cholinergic overdrive since i believe that TC-5214 is a non-competitive antagonist of nicotinic receptors. Will this mechanism of antagonism prevent the up-regulation of nicotinic receptors that hinders long term success with current nicotinic antagonists?
>
> Also, i don't really understand what it takes to get a new drug onto the market so is anyone able to shed any light on the probability of this drug making it into production?
>
> thanks
>
> rover
>
I find this interesting since bupropion helped me greatly for a little while when I added it to citalopram. I often wonder whether it was the nicotinic receptor antagonist properties it is thought to have, since that was the one thing about the drug I can point to as uniquely different than most other ADs I've taken.Bob
poster:Bob
thread:951636
URL: http://www.dr-bob.org/babble/20100615/msgs/951811.html